IWBCIS: Implantable wireless brain-computer interface systems
Study summary
Objectives of Study: This trial aims to evaluate the safety and efficacy of an implantable wireless brain-computer interface system in patients with tetraplegia resulting from spinal cord injury.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years and ≤65 years, male or female;
* Tetraplegia due to C2-C5 cervical spinal cord injury, diagnosed per 2019 revised ISNCSCI of ASIA, injury grade A to B;
* Intact cognitive function, MoCA-BLIND score ≥19;
* Elbow flexor muscle strength ≤ Grade 3 by ISNCSCI;
* Neurological assessment confirms normal motor cortex function without significant organic or functional brain lesions;
* Tetraplegia diagnosed for ≥12 months, stable clinical status ≥6 months after standard treatment;
* Good compliance, voluntary participation; informed consent signed by subject or legal representative.
Exclusion Criteria:
* Syringomyelia, severe neuralgia or spasticity limiting training participation;
* Require tracheotomy, mechanical ventilation, nasogastric feeding to sustain vital functions;
* High surgical risk: active systemic infection, coagulation disorders, antithrombotic therapy users;
* Subjects implanted with CNS electrical stimulation medical devices;
* Unstable medical conditions, severe mental/cognitive disorders confounding endpoint assessment;
* Severe, unstable, uncontrolled complex regional pain syndrome;
* Autoimmune-induced spinal cord dysfunction/injury;
* History of stroke, multiple sclerosis, drug-resistant epilepsy, Alzheimer's Disease;
* Peripheral neuropathy;
* Pregnant/breastfeeding females, females planning pregnancy during trial;
* Require MRI examinations during device implantation period;
* Participated in other clinical trials within 1 month prior to enrollment;
* Investigator judges participation unsafe, or subject unlikely to complete protocol follow-up.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.